
Julie Zhen Qin Wu
Examiner (ID: 7066)
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1643, 1642 |
| Total Applications | 417 |
| Issued Applications | 227 |
| Pending Applications | 26 |
| Abandoned Applications | 174 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 10676489
[patent_doc_number] => 20160022635
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-01-28
[patent_title] => 'USE OF ARGININE VASOPRESSIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PROSTATE CANCER'
[patent_app_type] => utility
[patent_app_number] => 14/811354
[patent_app_country] => US
[patent_app_date] => 2015-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 15056
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14811354
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/811354 | Use of arginine vasopressin receptor antagonists for the treatment of prostate cancer | Jul 27, 2015 | Issued |
Array
(
[id] => 10712612
[patent_doc_number] => 20160058759
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-03-03
[patent_title] => 'GLUTAMINASE INHIBITOR THERAPY'
[patent_app_type] => utility
[patent_app_number] => 14/791307
[patent_app_country] => US
[patent_app_date] => 2015-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 32907
[patent_no_of_claims] => 48
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14791307
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/791307 | GLUTAMINASE INHIBITOR THERAPY | Jul 2, 2015 | Abandoned |
Array
(
[id] => 10406656
[patent_doc_number] => 20150291665
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-10-15
[patent_title] => 'THERAPY OF CANCER BASED ON TARGETING ADAPTIVE, INNATE AND/OR REGULATORY COMPONENT OF THE IMMUNE RESPONSE'
[patent_app_type] => utility
[patent_app_number] => 14/749258
[patent_app_country] => US
[patent_app_date] => 2015-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 17808
[patent_no_of_claims] => 57
[patent_no_of_ind_claims] => 30
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14749258
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/749258 | Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response | Jun 23, 2015 | Issued |
Array
(
[id] => 10474833
[patent_doc_number] => 20150359851
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-12-17
[patent_title] => 'METHODS OF TREATING VESTIBULAR SCHWANNOMA AND REDUCING HEARING OR NEURITE LOSS CAUSED BY VESTIBULAR SCHWANNOMA'
[patent_app_type] => utility
[patent_app_number] => 14/741332
[patent_app_country] => US
[patent_app_date] => 2015-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 61989
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14741332
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/741332 | Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma | Jun 15, 2015 | Issued |
Array
(
[id] => 10399799
[patent_doc_number] => 20150284809
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-10-08
[patent_title] => 'MOLECULAR BIOMARKER SET FOR EARLY DETECTION OF OVARIAN CANCER'
[patent_app_type] => utility
[patent_app_number] => 14/734190
[patent_app_country] => US
[patent_app_date] => 2015-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 18106
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14734190
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/734190 | Molecular biomarker set for early detection of ovarian cancer | Jun 8, 2015 | Issued |
Array
(
[id] => 10374429
[patent_doc_number] => 20150259434
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-09-17
[patent_title] => 'Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof'
[patent_app_type] => utility
[patent_app_number] => 14/727135
[patent_app_country] => US
[patent_app_date] => 2015-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 36
[patent_no_of_words] => 52202
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14727135
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/727135 | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof | May 31, 2015 | Issued |
Array
(
[id] => 10389832
[patent_doc_number] => 20150274838
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-10-01
[patent_title] => 'Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof'
[patent_app_type] => utility
[patent_app_number] => 14/727032
[patent_app_country] => US
[patent_app_date] => 2015-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 36
[patent_no_of_words] => 52254
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14727032
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/727032 | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof | May 31, 2015 | Issued |
Array
(
[id] => 10656194
[patent_doc_number] => 20160002338
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-01-07
[patent_title] => 'ANTI-HER3 ANTIBODIES BINDING TO THE BETA-HAIRPIN OF HER3'
[patent_app_type] => utility
[patent_app_number] => 14/710194
[patent_app_country] => US
[patent_app_date] => 2015-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 38716
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14710194
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/710194 | Anti-HER3 antibodies binding to the beta-hairpin of HER3 | May 11, 2015 | Issued |
Array
(
[id] => 11471242
[patent_doc_number] => 20170058025
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-03-02
[patent_title] => 'METHODS OF USING ANTI-ANG2 ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 15/308187
[patent_app_country] => US
[patent_app_date] => 2015-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 11408
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15308187
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/308187 | METHODS OF USING ANTI-ANG2 ANTIBODIES | May 5, 2015 | Abandoned |
Array
(
[id] => 11873620
[patent_doc_number] => 09745377
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-08-29
[patent_title] => 'Immunological compositions as cancer therapeutics'
[patent_app_type] => utility
[patent_app_number] => 14/704541
[patent_app_country] => US
[patent_app_date] => 2015-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 19676
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14704541
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/704541 | Immunological compositions as cancer therapeutics | May 4, 2015 | Issued |
Array
(
[id] => 11471262
[patent_doc_number] => 20170058046
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-03-02
[patent_title] => 'ERBB2 SIGNALING AND NERVE REGENERATION'
[patent_app_type] => utility
[patent_app_number] => 15/308267
[patent_app_country] => US
[patent_app_date] => 2015-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 9385
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15308267
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/308267 | ERBB2 SIGNALING AND NERVE REGENERATION | May 3, 2015 | Abandoned |
Array
(
[id] => 10422610
[patent_doc_number] => 20150307621
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-10-29
[patent_title] => 'ANTI-CD98 ANTIBODY PROCESSES'
[patent_app_type] => utility
[patent_app_number] => 14/703354
[patent_app_country] => US
[patent_app_date] => 2015-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 20964
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14703354
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/703354 | Anti-CD98 antibody processes | May 3, 2015 | Issued |
Array
(
[id] => 15468667
[patent_doc_number] => 10550196
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-02-04
[patent_title] => Humanized antibodies against CEACAM1
[patent_app_type] => utility
[patent_app_number] => 15/306664
[patent_app_country] => US
[patent_app_date] => 2015-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 25
[patent_no_of_words] => 22185
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15306664
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/306664 | Humanized antibodies against CEACAM1 | Apr 26, 2015 | Issued |
Array
(
[id] => 16276830
[patent_doc_number] => 10759844
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-01
[patent_title] => Disulfide stabilised antibodies and fragments thereof
[patent_app_type] => utility
[patent_app_number] => 14/697092
[patent_app_country] => US
[patent_app_date] => 2015-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 1
[patent_no_of_words] => 9099
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 185
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14697092
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/697092 | Disulfide stabilised antibodies and fragments thereof | Apr 26, 2015 | Issued |
Array
(
[id] => 16244876
[patent_doc_number] => 10744204
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-08-18
[patent_title] => Conjugated compounds comprising cysteine-engineered antibodies
[patent_app_type] => utility
[patent_app_number] => 15/302036
[patent_app_country] => US
[patent_app_date] => 2015-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 37
[patent_no_of_words] => 35044
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15302036
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/302036 | Conjugated compounds comprising cysteine-engineered antibodies | Apr 9, 2015 | Issued |
Array
(
[id] => 10325763
[patent_doc_number] => 20150210767
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-07-30
[patent_title] => 'STABLE ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS'
[patent_app_type] => utility
[patent_app_number] => 14/682176
[patent_app_country] => US
[patent_app_date] => 2015-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29386
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14682176
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/682176 | STABLE ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS | Apr 8, 2015 | Abandoned |
Array
(
[id] => 10457978
[patent_doc_number] => 20150342993
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-12-03
[patent_title] => 'COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY'
[patent_app_type] => utility
[patent_app_number] => 14/676255
[patent_app_country] => US
[patent_app_date] => 2015-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 18775
[patent_no_of_claims] => 53
[patent_no_of_ind_claims] => 43
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14676255
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/676255 | Compositions and methods for immunotherapy | Mar 31, 2015 | Issued |
Array
(
[id] => 10422618
[patent_doc_number] => 20150307629
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-10-29
[patent_title] => 'Bispecific antibodies that bind to CD38 and CD3'
[patent_app_type] => utility
[patent_app_number] => 14/673695
[patent_app_country] => US
[patent_app_date] => 2015-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 161
[patent_figures_cnt] => 161
[patent_no_of_words] => 33420
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14673695
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/673695 | Bispecific antibodies that bind to CD38 and CD3 | Mar 29, 2015 | Issued |
Array
(
[id] => 10414325
[patent_doc_number] => 20150299335
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-10-22
[patent_title] => 'BI-SPECIFIC ANTIGEN-BINDING POLYPEPTIDES'
[patent_app_type] => utility
[patent_app_number] => 14/664018
[patent_app_country] => US
[patent_app_date] => 2015-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 16044
[patent_no_of_claims] => 44
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14664018
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/664018 | Bi-specific antigen-binding polypeptides | Mar 19, 2015 | Issued |
Array
(
[id] => 12165316
[patent_doc_number] => 09884075
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-02-06
[patent_title] => 'Domain-swap T cell receptors'
[patent_app_type] => utility
[patent_app_number] => 14/597908
[patent_app_country] => US
[patent_app_date] => 2015-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 15458
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 171
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14597908
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/597908 | Domain-swap T cell receptors | Jan 14, 2015 | Issued |